<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Alpha-1 proteinase inhibitor: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Alpha-1 proteinase inhibitor: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Alpha-1 proteinase inhibitor: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11164" href="/d/html/11164.html" rel="external">see "Alpha-1 proteinase inhibitor: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F131976"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Aralast NP;</li>
<li>Glassia;</li>
<li>Prolastin-C;</li>
<li>Zemaira</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52865610"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Prolastin-C</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F131989"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antitrypsin Deficiency Agent;</li>
<li>
                        Blood Product Derivative</li></ul></div>
<div class="block doa drugH1Div" id="F131978"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note: </b>The vial strength (mg) of some products (ie, Prolastin-C, Zemaira) varies by manufacturer lot; consult individual vial labels for exact amount prior to preparation for administration.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1922b43b-a16c-4aa3-9f48-5ba897f2375c">Alpha<sub>1</sub>-antitrypsin deficiency</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Alpha<sub>1</sub>-antitrypsin deficiency:</b> IV: 60 mg/kg once weekly</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990648"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50987858"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doe drugH1Div" id="F131979"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F131956"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest discomfort, chest pain, peripheral edema, vasodilation</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus, skin rash, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hot flash</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distention, abdominal pain, diarrhea, nausea, oral candidiasis</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Dysmenorrhea, urinary tract infection</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased liver enzymes (including increased serum alanine aminotransferase, increased serum aspartate aminotransferase)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development (including neutralizing)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Bleeding at injection site, bruising at injection site</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Asthenia, cerebral ischemia, chills, dizziness, drowsiness, fatigue, headache, hypertonia, hypoesthesia, insomnia, lethargy, nervousness, seizure</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain, musculoskeletal pain (discomfort)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Conjunctivitis, visual disturbance</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Tinnitus</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Asthma, bronchitis, cough, dyspnea, exacerbation of chronic obstructive pulmonary disease, lower respiratory tract infection, nasopharyngitis, pharyngitis, rhinitis, rhinorrhea, sinusitis, upper respiratory tract infection</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Flushing, increased blood pressure, swelling of extremities, tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Exfoliative dermatitis, hyperhidrosis</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, facial edema, hypersensitivity angiitis (Mwirigi 2009), lip edema, nonimmune anaphylaxis</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Lymph node pain</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Infusion-site reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Malaise, pain, paresthesia</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia, myalgia</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Periorbital swelling</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Flu-like symptoms, hemoptysis (Mwirigi 2009), wheezing (Mwirigi 2009)</p></div>
<div class="block coi drugH1Div" id="F131966"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">History of anaphylaxis or other severe systemic reaction to A<sub>1</sub>-proteinase inhibitor or any component of the formulation; IgA deficient patients with antibodies against IgA.</p></div>
<div class="block war drugH1Div" id="F131953"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Severe hypersensitivity and anaphylactic/anaphylactoid reactions may occur; stop infusion promptly for acute hypersensitivity; immediate treatment (including epinephrine and/or other supportive therapy) should be available. Monitor vital signs and observe the patient throughout the infusion. May contain trace amounts of IgA; patients with known anti-IgA antibody, which may be present in patients with selective or severe IgA deficiency, have an increased risk of developing potentially severe hypersensitivity and anaphylactic reactions.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Fluid overload: Plasma volume may increase following infusion; use with caution in patients at risk for fluid overload.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Human plasma: Product of human plasma; may potentially contain infectious agents which could transmit disease (eg, viruses and theoretically the Creutzfeldt-Jakob disease [CJD]). Screening of donors, as well as testing and/or inactivation or removal of certain viruses, reduces the risk. Infections thought to be transmitted by this product should be reported to the manufacturer.</p></div>
<div class="block dosfc drugH1Div" id="F50620846"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Strengths expressed with approximate values. Consult individual vial labels for exact potency within each vial.</p></div>
<div class="block foc drugH1Div" id="F131961"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Glassia: 1000 mg/50 mL (1 ea) [latex free]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Prolastin-C: 1000 mg/20 mL (1 ea) [latex free, pyrogen free]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Aralast NP: 500 mg (1 ea); 1000 mg (1 ea) [contains polyethylene glycol (macrogol), polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Prolastin-C: 1000 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zemaira: 1000 mg (1 ea); 4000 mg (1 ea); 5000 mg (1 ea)</p></div>
<div class="block geq drugH1Div" id="F131949"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16322971"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Glassia Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1000 mg/50 mL (0 Price provided is per milligram): $0.77</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Prolastin-C Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1000 mg/20 mL (0 Price provided is per milligram): $0.68</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Aralast NP Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (0 Price provided is per milligram): $0.76</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1000 mg (0 Price provided is per milligram): $0.76</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Prolastin-C Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1000 mg (0 Price provided is per milligram): $0.62</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Zemaira Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1000 mg (0 Price provided is per milligram): $0.67</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4000 mg (0 Price provided is per milligram): $0.67</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5000 mg (0 Price provided is per milligram): $0.67</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52865611"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Prolastin-C: 1000 mg (1 ea)</p></div>
<div class="block adm drugH1Div" id="F131963"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">IV: For IV infusion only. Do not mix with other agents or solutions. If adverse reactions occur during administration, rate may be decreased or temporarily interrupted. Some products require an in-line filter for administration; consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Aralast NP, Glassia: Infuse at rate of ≤0.2 mL/kg/minute. Glassia may be self-administered by the patient/caregiver at home after appropriate training</p>
<p style="text-indent:-2em;margin-left:2em;">Prolastin-C, Zemaira: Infuse at ~0.08 mL/kg/minute (rate may be increased or decreased based on patient comfort).</p>
<p style="text-indent:-2em;margin-left:2em;">Prolastin-C Liquid: Infuse at 0.08 mL/kg/minute (takes ~15 minutes to infuse) as determined by patient response and comfort. Allow vial to warm to room temperature before administration; solution may contain a few protein particles.</p></div>
<div class="block use drugH1Div" id="F131962"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Alpha<sub>1</sub>-proteinase inhibitor deficiency:</b> Long-term augmentation and maintenance therapy in adults with severe hereditary deficiency of alpha<sub>1</sub>-antitrypsin (AAT) with clinically evident emphysema.</p>
<p style="text-indent:-2em;margin-left:2em;">Limitations of use:</p>
<p style="text-indent:-2em;margin-left:4em;">Not indicated as therapy for patients with lung disease in whom hereditary AAT deficiency has not been established; long-term effects of chronic augmentation or maintenance therapy of individuals with alpha<sub>1</sub>-proteinase inhibitor are not available.</p>
<p style="text-indent:-2em;margin-left:4em;">The effect of augmentation therapy with any alpha<sub>1</sub>-proteinase inhibitor on pulmonary exacerbations and the progression of emphysema in alpha<sub>1</sub>-proteinase inhibitor deficiency has not been demonstrated in randomized, controlled clinical trials. However, one randomized controlled trial showed a reduction in emphysema progression with alpha<sub>1</sub>-proteinase inhibitor augmentation therapy when CT lung density was measured at total lung capacity (Chapman 2015).</p></div>
<div class="block cyt drugH1Div" id="F13298714"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F6217702"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block pri drugH1Div" id="F131967"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Animal reproduction studies have not been conducted.</p></div>
<div class="block brc drugH1Div" id="F21098360"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if alpha<sub>1</sub>-proteinase inhibitor is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></div>
<div class="block dic drugH1Div" id="F131968"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;text-align:justify;display:inline">Some products may contain sodium.</p></div>
<div class="block mop drugH1Div" id="F131959"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Alpha<sub>1</sub>-PI serum levels; lung function; vital signs during infusion</p></div>
<div class="block pha drugH1Div" id="F131952"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Alpha<sub>1</sub>-antitrypsin (AAT) is the principle protease inhibitor in  serum. Its major physiologic role is to render proteolytic enzymes (secreted during inflammation) inactive. A decrease in AAT, as seen in congenital AAT deficiency, leads to increased elastic damage in the lung, causing emphysema.</p></div>
<div class="block phk drugH1Div" id="F131965"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 3.2 ± 0.3 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Metabolic: ~5 to 6 days; terminal: 111 ± 33 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: ~1 hour; threshold levels achieved after 3 weeks.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F131969"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Aralast | Glassia | Prolastin | Trypsan</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Prolastin | Respreeza</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Pulmolast</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Prolastin c | Trypsone | Ventia | Zemaira</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Prolastin | Respreeza</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Prolastin c | Ventia | Zemaira</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Respreeza</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Respreeza</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Prolasplan | Prolastina | Respreeza | Trypsone</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Prolastina</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Alfalastin | Prolastin | Prolastin c | Respreeza</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Respreeza</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Prolastin | Respreeza</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Respreeza</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Respreeza</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Prolastin | Prolastina | Respreeza</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Trypsone | Zemaira</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Prolastin | Respreeza</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Respreeza</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Glassia | Prolastin | Prolastin c</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Prolastin | Respreeza</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Respikam</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Prolastine c</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Prolastina</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Respreeza</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Prolastin c</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-14522813">
<a name="14522813"></a>American Thoracic Society/European Respiratory Society Statement: “Standards for the Diagnosis and Management of Individuals With Alpha-1 Antitrypsin Deficiency,” <i>Am J Respir Crit Care Med</i>, 2003, 168(7):818-900.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alpha-1-proteinase-inhibitor-drug-information/abstract-text/14522813/pubmed" id="14522813" target="_blank">14522813</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AralastNP.1">
<a name="AralastNP.1"></a>Aralast NP (alpha<sub>1</sub>-proteinase inhibitor, human) [prescribing information]. Lexington, MA: Takeda Pharmaceuticals USA Inc; March 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26026936">
<a name="26026936"></a>Chapman KR, Burdon JG, Piitulainen E, et al. Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial. <i>Lancet</i>. 2015;386(9991):360-368.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alpha-1-proteinase-inhibitor-drug-information/abstract-text/26026936/pubmed" id="26026936" target="_blank">26026936</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Glassia (alpha<sub>1</sub>-proteinase inhibitor, human) [prescribing information]. Lexington, MA: Takeda Pharmaceuticals USA Inc; September 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16219903">
<a name="16219903"></a>Louie SG, Sclar DA, and Gill MA, “Aralast: A New Alpha1-Protease Inhibitor for Treatment of Alpha-Antitrypsin Deficiency,” <i>Ann Pharmacother</i>, 2005, 39(11):1861-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alpha-1-proteinase-inhibitor-drug-information/abstract-text/16219903/pubmed" id="16219903" target="_blank">16219903</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20204065">
<a name="20204065"></a>Mwirigi NW, Thomas CF. Hypersensitivity vasculitis with leukocytoclastic vasculitis associated with alpha-1-proteinase inhibitor. <i>Case Rep Med</i>. 2009;2009:941258. doi:10.1155/2009/941258<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alpha-1-proteinase-inhibitor-drug-information/abstract-text/20204065/pubmed" id="20204065" target="_blank">20204065</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Prolastin-C (alpha<sub>1</sub>-proteinase inhibitor, human) [prescribing information]. Research Triangle Park, NC: Grifols Therapeutics, Inc; January 2022.</div>
</li>
<li>
<div class="reference">
                  Prolastin-C Liquid (alpha<sub>1</sub>-proteinase inhibitor, human) [prescribing information]. Research Triangle Park, NC: Grifols Therapeutics LLC; May 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15978931">
<a name="15978931"></a>Stoller JK and Aboussouan LS, “Alpha1-Antitrypsin Deficiency,” <i>Lancet</i>, 2005, 365(9478):2225-36.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alpha-1-proteinase-inhibitor-drug-information/abstract-text/15978931/pubmed" id="15978931" target="_blank">15978931</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Zemaira (alpha<sub>1</sub>-proteinase inhibitor, human) [prescribing information]. Kankakee, IL: CSL Behring; September 2022.</div>
</li></ol></div><div id="topicVersionRevision">Topic 8495 Version 205.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
